The sudden cancellation of an NIH-funded Tulane research program cut short vital long COVID studies and derailed early-career scientists, leaving major gaps in understanding a condition affecting millions.
An NIH funded research program at Tulane University—originally awarded approximately $1 million per year over five years—was terminated abruptly in March 2025, eliminating the final six months of support for a multidisciplinary team studying immune responses to COVID-19 and the biological mechanisms underlying long COVID. The cancellation halted ongoing collection and analysis of longitudinal blood samples from patients with long COVID, a critical effort to understand how immune function and immune metabolism evolve over time in those experiencing prolonged symptoms. This work had the potential to deepen understanding of why long COVID develops, identify biological markers of disease progression, and lay the groundwork for future therapeutic strategies. Because funding ended midstream, researchers were unable to complete follow-up with enrolled participants or generate the full set of data needed to answer foundational questions about disease progression and immune response evolution.
The termination also created significant disruption for early-career scientists whose salaries depended on this federal support. Junior investigators lost essential funding that departments rely on to support faculty positions, introducing instability at a critical stage in their careers. Although the university worked to mitigate immediate job losses, the sudden funding cut effectively derailed the professional momentum of younger scientists and forced the research team to abandon promising lines of inquiry into long-term immunity and the biological drivers of long COVID. As a result, the scientific community—and ultimately patients—lost an opportunity to advance understanding of a condition affecting millions of people in the United States and around the world.